Ect2 Antibody (E-1): sc-514769
- Ect2 Antibody (E-1) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- raised against amino acids 584-883 of Ect2 of human origin
- recommended for detection of Ect2 of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for Ect2 Antibody (E-1) for WB applications. These reagents are now offered in bundles with Ect2 Antibody (E-1) (see ordering information below).
QUICK LINKS
SEE ALSO...
Ect2 Antibody (E-1) is a mouse monoclonal IgG1 antibody that detects Ect2 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Ect2 plays a crucial role in regulating the cell cycle and is particularly important for cytokinesis, the process by which a cell divides its cytoplasm to form two daughter cells. This function is vital for maintaining proper cell division and preventing aneuploidy, which can lead to cancer and other diseases. Ect2 contains both Dbl homology (DH) and pleckstrin homology (PH) domains, which are essential for interaction with small GTPases like Rho and Rac. These interactions are critical for the organization of the cytoskeleton during cell division. Anti-Ect2 antibody (E-1) provides reliable detection of Ect2, facilitating research into cell cycle regulation and implications in oncogenesis.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Ect2 Antibody (E-1) References:
- Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma. | Justilien, V., et al. 2017. Cancer Cell. 31: 256-269. PMID: 28110998
- A feedforward circuit shaped by ECT2 and USP7 contributes to breast carcinogenesis. | Zhang, Q., et al. 2020. Theranostics. 10: 10769-10790. PMID: 32929379
- Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention. | Wang, H., et al. 2020. Onco Targets Ther. 13: 12905-12918. PMID: 33376345
- The BRCT domains of ECT2 have distinct functions during cytokinesis. | Schneid, S., et al. 2021. Cell Rep. 34: 108805. PMID: 33657383
- Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. | Cook, DR., et al. 2022. Cancer Res. 82: 90-104. PMID: 34737214
- Integrated Analysis of ECT2 and COL17A1 as Potential Biomarkers for Pancreatic Cancer. | Huang, WL., et al. 2022. Dis Markers. 2022: 9453549. PMID: 35722628
- ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer. | Liu, X., et al. 2023. Cancer Gene Ther. 30: 62-73. PMID: 36056253
- miRNA-223-3p regulates ECT2 to promote proliferation, invasion, and metastasis of gastric cancer through the Wnt/β-catenin signaling pathway. | Li, L., et al. 2023. J Cancer Res Clin Oncol. 149: 121-134. PMID: 36355210
- m6A readers ECT2/ECT3/ECT4 enhance mRNA stability through direct recruitment of the poly(A) binding proteins in Arabidopsis. | Song, P., et al. 2023. Genome Biol. 24: 103. PMID: 37122016
- ECT2 promotes the occurrence and is a prognostic biomarker of head and neck squamous cell carcinoma. | Peng, S., et al. 2024. J Cancer. 15: 4156-4174. PMID: 38947403
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ect2 Antibody (E-1) | sc-514769 | 200 µg/ml | $322.00 | |||
Ect2 Antibody (E-1): m-IgG Fc BP-HRP Bundle | sc-540991 | 200 µg Ab; 10 µg BP | $361.00 | |||
Ect2 Antibody (E-1): m-IgG1 BP-HRP Bundle | sc-542515 | 200 µg Ab; 20 µg BP | $361.00 |